Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult P

At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales. The guidance from NICE states that aficamten can be used as an option to treat symptomatic oHCM in eligible adults with a NYHA class of II to III. It can only be used as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or alone if these treatments are contraindicated, and if the company provides it according to the commercial arrangement. "We are pleased to have secured a marketing authorisation for aficamten and to see positive guidance from NICE for eligible adult patients in England and Wales," said Joseph Dagher, Senior Vice President and Head of Europe, Cytokinetics. "We are grateful for the collaborations that made th...